Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice

Magnetic Resonance in Medicine

Volumn 62, Issue 3, 2009, Pages 616-625

  Sennino, Barbara ^a   Raatschen, Hans Juergen ^b   Wendland, Michael F ^b   Fu, Yanjun ^b   You, Weon Kyoo ^a   Shames, David M ^b   McDonald, Donald M ^a   Brasch, Robert C ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood lakes; Dynamic MRI; Fractional plasma volume; Lectin; MMCM; RIP Tag2 tumors

Indexed keywords

BLOOD VESSELS; CONTRAST MEDIA; LAKES; MAGNETIC RESONANCE IMAGING; MAMMALS; PROTEINS; TUMORS;

DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; DYNAMIC MRI; ENDOTHELIAL PERMEABILITY; LECTIN; MICROSCOPIC MEASUREMENT; MMCM; PLASMA VOLUME; TWO-COMPARTMENT MODELS;

BLOOD;

BIOTIN DERIVATIVE; CONTRAST MEDIUM; GADOLINIUM PENTETATE ALBUMIN; LECTIN;

ANIMAL MODEL; ARTICLE; BIOTINYLATION; BLOOD; CLINICAL ASSESSMENT; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DENSITY GRADIENT; DIAGNOSTIC VALUE; DYNAMIC CONTRAST IMAGING; ENDOTHELIUM; ERYTHROCYTE; FEASIBILITY STUDY; IMMUNOHISTOCHEMISTRY; MACROMOLECULE; MEMBRANE PERMEABILITY; MICROSCOPY; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; PANCREAS TUMOR; PLASMA VOLUME; TRANSGENIC ANIMAL; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 69449093553     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22040     Document Type: Article

References (30)

1. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-122. (Pubitemid 15064530)
2. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 1998;42:995-1002. (Pubitemid 28530755)
3. Ludlow JW. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J 1993;7:866-871. (Pubitemid 23225542)
4. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-1380. (Pubitemid 30660013)
5. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A:2386-2393. (Pubitemid 27080776)
6. Preda A, van Vliet M, Krestin GP, Brasch RC, van Dijke CF. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol 2006;41:325-331. (Pubitemid 44406194)
7. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, Wendland MF, McDonald DM, Brasch RC. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008;247:391-399.
8. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25:319-327. (Pubitemid 46413652)
9. Fournier LS, Novikov V, Lucidi V, Fu Y, Miller T, Floyd E, Shames DM, Brasch RC. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology 2007;243:105-111. (Pubitemid 46579700)
10. Wiart M, Fournier LS, Novikov VY, Shames DM, Roberts TP, Fu Y, Shalinsky DR, Brasch RC. Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor Prinomastat. Technol Cancer Res Treat 2004;3:377-382. (Pubitemid 39096610)
11. Cyran CC, Sennino B, Chaopathomkul B, Fu Y, Rogut VS, Shames DM, Wendland MF, McDonald DM, Brasch RC. Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. Eur Radiol 2009;19:121-131.
12. Ogan MD. Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1988;23:961.
13. Schmiedl U, Brasch RC, Ogan MD, Moseley ME. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool and perfusion imaging. Acta Radiol Suppl 1990;374:99-102.
14. van Dijke CF, Mann JS, Rosenau W, Wendland MF, Roberts TP, Roberts HC, Demsar F, Brasch RC. Comparison of MR contrast-enhancing properties of albumin-(biotin)10-(gadopentetate)25, a macromolecular MR blood pool contrast agent, and its microscopic distribution. Acad Radiol 2002;9(Suppl 1):S257-260.
15. Cyran CC, Sennino B, Chaopathomkul B, Fu Y, Rogut V, Shames DM, Wendland MF, McDonald DM, Brasch RC. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature. Invest Radiol 2008;43:298-305. (Pubitemid 351572206)
16. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland MF, Carter WO, Brasch RC. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging 2001;14:237-242. (Pubitemid 32801057)
17. Schwickert HC, Roberts TP, Shames DM, van Dijke CF, Disston A, Muhler A, Mann JS, Brasch RC. Quantification of liver blood volume: comparison of ultra short TI inversion recovery echo planar imaging (ULSTIR-EPI), with dynamic 3D-gradient recalled echo imaging. Magn Reson Med 1995;34:845-852.
18. Roberts TP, Brasch RC, Schwickert HC, Shames DM, vanDijke CF, Stiskal M, Mann JS, Muhler A, Demsar F. Quantification of tissue gadolinium concentration using magnetic resonance imaging: comparison of ultrashort inversion time inversion recovery echoplanar and dynamic three-dimensional spoiled gradient-recalled approaches with in vitro measurements. Acad Radiol 1996;3(Suppl 2):S282-285.
19. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 1998;28:67-78. (Pubitemid 28077437)
20. Daldrup HE, Shames DM, Husseini W, Wendland MF, Okuhata Y, Brasch RC. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 1998;40:537-543. (Pubitemid 28440021)
21. Cobelli C, Foster D, Toffolo G. Tracer kinetics in biomedical research. New York: Kluwer Academic/Plenum Publishers; 2000.
22. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52. (Pubitemid 38821812)
23. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-2621. (Pubitemid 44511625)
24. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-812. (Pubitemid 29291347)
25. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295. (Pubitemid 36554699)
26. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007;67:7358-7367. (Pubitemid 47206566)
27. Cao X, Jia G, Zhang T, Yang M, Wang B, Wassenaar PA, Cheng H, Knopp MV, Sun D. Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol 2008;62:985-994.
28. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
29. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305. (Pubitemid 16076428)
30. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, Delattre O, Maxwell PH, Hendrix MJ, Griffioen AW. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 2005;65:11520-11528. (Pubitemid 41821710)